Fused Or Hybrid Cell, Per Se Patents (Class 435/346)
-
Publication number: 20090004237Abstract: The present invention provides B7-Like (B7-L) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing B7-L polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with B7-L polypeptides.Type: ApplicationFiled: June 27, 2008Publication date: January 1, 2009Applicant: AMGEN, INC.Inventors: Gary M. Fox, John K. Sullivan, Paige Holst, Steven Kiyoshi Yoshinaga
-
Publication number: 20080317751Abstract: The present application relates to immunoglobulin polypeptides comprising at least two immunoglobulin complementarity determining regions, one that binds to an immune receptor and the other which comprises an idiotype to which an immune response is desired.Type: ApplicationFiled: June 15, 2006Publication date: December 25, 2008Inventor: Andrew William Heath
-
Publication number: 20080293036Abstract: The present invention provides monoclonal antibodies to HIV-1 Vpr and hybridoma cell lines that produce the monoclonal antibodies to HIV-1 Vpr. Methods for use of such antibodies in the detection of HIV-1 infection are also provided.Type: ApplicationFiled: June 22, 2005Publication date: November 27, 2008Inventors: Jeffrey B. Kopp, Terence M. Phillips, Ulrich Schubert, John Yewell
-
Publication number: 20080293162Abstract: Methods and compositions for determining whether a subject at least has a neoplastic disease are provided. In practicing the subject methods, a sample from a subject is assayed for a soluble filamin analyte, such as a filamin A analyte, to determine whether the subject at least has the neoplastic disease. Also provided are kits, systems, and devices for practicing the subject methods.Type: ApplicationFiled: August 8, 2008Publication date: November 27, 2008Applicant: INVITROGEN CORPORATIONInventor: Ozge ALPER
-
Publication number: 20080292641Abstract: Hybridoma lines that secrete human monoclonal antibodies with high binding specificity and biological activity, particularly neutralizing activity against granulocyte-macrophage colony stimulating factor, and methods of generating the hybridoma lines are provided. Target antigens and epitopes are also provided. The antibodies may be used in therapeutic methods, for example in the treatment of cancer, infectious disease, or autoimmune disease.Type: ApplicationFiled: February 8, 2007Publication date: November 27, 2008Applicant: Morphotek, Inc.Inventors: Philip M. Sass, Nicholas C. Nicolaides, Luigi Grasso, Jian Li, Qimin Chao, Eric Routhier, Wolfgang Ebel
-
Publication number: 20080286813Abstract: The present invention describes the identification, isolation, cloning, and determination of the Alzheimer Related Membrane Protein (ARMP) gene on chromosome 14 and a related gene, E5-1, on chromosome 1. Normal and mutant copies of both genes are presented. Transcripts and products of these genes are useful in detecting and diagnosing Alzheimer's disease, developing therapeutics for treatment of Alzheimer's disease, as well as the isolation and manufacture of the protein and the construction of transgenic animals expressing the mutant genes.Type: ApplicationFiled: August 20, 2007Publication date: November 20, 2008Inventors: Peter H. St. George-Hyslop, Johanna M. Rommens, Paul E. Fraser
-
Publication number: 20080286805Abstract: Accordingly, the invention provides constructs in which the nucleic acids encoding Plasmodium falciparum MSP4 and MSP5, and the resulting polypeptides, have been modified. More particularly, this invention provides constructs encoding recombinant MSP4 and MSP5 polypeptides, which are expressed as soluble, secreted polypeptides in a baculovirus-insect cell expression system. It was surprisingly found that the recombinant polypeptides contain an EGF-like domain at the C-terminus that is properly folded in the polypeptide.Type: ApplicationFiled: November 22, 2006Publication date: November 20, 2008Inventors: Shirley Longacre, Hannah Polson, Ronald Perraut, Faridabano Nato
-
Publication number: 20080287391Abstract: It is intended to provide a regeneration promoter for regenerating a tissue with the use of somatic stem cells. It is also intended to provide a cell fusion promoter safely usable in vivo. Namely, it is intended to provide a cell fusion promoter comprising ATP or its metabolite. A cell fusion promoter comprising ATP or its metabolite and a method of producing fused cells in the presence of ATP or its metabolite. A medicinal composition for regenerating or improving the function of a tissue or an organ, which suffers from dysfunction or hypofunction due to injury or denaturation, by using stem cells. This composition comprises ATP or its metabolite and a pharmaceutically acceptable carrier.Type: ApplicationFiled: July 12, 2005Publication date: November 20, 2008Applicants: KOWA COMPANY, LTD.Inventors: Masafumi Kitakaze, Tetsuo Minamino, Akio Hirata
-
Publication number: 20080286284Abstract: The invention includes antibodies or antigen-binding fragments thereof which bind specifically to conformational epitopes on the extracellular domain of PSMA, compositions containing one or a combination of such antibodies or antigen-binding fragments thereof, hybridoma cell lines that produce the antibodies, and methods of using the antibodies or antigen-binding fragments thereof for cancer diagnosis and treatment. The invention also includes oligomeric forms of PSMA proteins, compositions comprising the multimers, and antibodies that selectively bind to the multimers.Type: ApplicationFiled: November 7, 2007Publication date: November 20, 2008Applicants: PSMA Development Company, LLC, Amgen Fremont Inc.Inventors: Paul J. Maddon, Gerald P. Donovan, William C. Olson, Norbert Schuelke, Jason Gardner, Dangshe Ma, Jaspal S. Kang, Larry Green
-
Publication number: 20080279857Abstract: The present invention relates to agents which modulate the effect of a RAMP (Receptor Activity Modifying Protein) protein on a Calcitonin Receptor Like Receptor (CRLR). Also included in the present invention are methods and uses of such agents and assays for identifying such agents. The agents of the present disclosure may be used in the treatment of, for example, cancer, obesity and other disorders.Type: ApplicationFiled: October 18, 2006Publication date: November 13, 2008Applicant: THE UNIVERSITY OF SHEFFIELDInventors: Timothy Michael Skerry, Gareth Owain Richards
-
Publication number: 20080274102Abstract: An antibody or antibody fragment preparation being capable of specifically binding the amino acid sequence 60-76, 86-98, 135-149, 215-227, 363-377, 385-397, 405-419, 427-440, 509-522, 605-619, 635-649, 666-680, 696-711, 752-766, 836-851, 871-884, and/or 904-916 of NIK, or being capable of specifically binding a specific portion of the amino acid sequence is provided.Type: ApplicationFiled: October 5, 2004Publication date: November 6, 2008Applicant: YEDA RESEARCH AND DEVELOPMENT CO., LTDInventors: David Wallach, Parameswaran Ramakrishnan
-
Patent number: 7445780Abstract: Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity when the antibody binds a CD40 antigen on a normal human B cell, exhibits antagonist activity when the antibody binds a CD40 antigen on a malignant human B cell, and can exhibit antagonist activity when the antibody binds a CD40 antigen on a normal human B cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of malignant human B cells.Type: GrantFiled: August 31, 2007Date of Patent: November 4, 2008Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Keting Chu, Lorianne K. Masuoka
-
Publication number: 20080268459Abstract: This invention provides anti-idiotype antibodies specific for Anti-Lewis Y monoclonal antibodies. The present invention also directed against an ELISA screening method of mAbs produced by hybridoma clones for specific binding to the variable regions of hu3S193 and the ability of the anti-idiotypic mAB to inhibit hu3S193 binding to Lewis Y antigen. Additionally, the present invention provides a hybridoma capable of producing an anti-idiotype antibody specific for anti-Lewis Y monoclonal antibody. A further aspect of the invention is to provide a hybridoma, which is specific for anti-Lewis Y monoclonal antibody selected from the group consisting of LMH-1, LMH-2, LMH-3, or LMH-4. The present invention is also directed against a method to detect HAMA, HACA and HAHA responses using the antibody of the invention.Type: ApplicationFiled: August 10, 2004Publication date: October 30, 2008Inventors: Zhanqi Liu, Andrew Mark Scott, Fiona E. Smyth
-
Publication number: 20080267930Abstract: A method of producing a reprogrammed cell or reprogrammed cell nucleus, comprising exposing a differentiated cell, or the nucleus of a differentiated cell to a cell or cell extract thereof derived from an oocyte, egg, ovary or early embryo of a cold blooded vertebrate, wherein the cold blooded vertebrate has one or more of the following properties: (i) a primitive vertebrate body plan including laterally projecting ribs and/or spinal projections; (ii) germ cells which do not contain germ plasm; and/or (iii) the oocyte, egg, ovary or early embryo cell or cell from which the cell extract is derived, expresses a highly conserved form of Oct-4 and/or nanog. There is also provided uses of the reprogrammed cells.Type: ApplicationFiled: July 21, 2006Publication date: October 30, 2008Applicant: The University of NottinghamInventors: Andrew Johnson, Keith Campbell, Ramiro Alberio
-
Publication number: 20080254048Abstract: Compositions and methods for diagnosing ovarian cancer in a patient and for identifying patients with an increased likelihood of having ovarian cancer are provided. The compositions include novel monoclonal antibodies, and variants and fragments thereof, that specifically bind to HE4. Monoclonal antibodies having the binding characteristics of an HE4 antibody of the invention are further provided. Hybridoma cell lines that produce an HE4 monoclonal antibody of the invention are also disclosed herein. The compositions find use in diagnostic methods as well as in screening methods for identifying patients having an increased likelihood of having ovarian cancer. Kits comprising one or more of the disclosed HE4 monoclonal antibodies and for practicing the methods of the invention are further provided. Polypeptides comprising the amino acid sequence for an HE4 epitope and methods of using these polypeptides in the production of antibodies are also encompassed by the present invention.Type: ApplicationFiled: March 7, 2008Publication date: October 16, 2008Applicant: TriPath Imaging, Inc.Inventors: Robert L. Cheek, Timothy J. Fischer, John W. Groelke
-
Publication number: 20080253962Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to IRTA-4 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting IRTA-4, as well as methods for treating various B cell malignancies, including non-Hodgkin's lymphoma.Type: ApplicationFiled: September 19, 2005Publication date: October 16, 2008Applicant: Medarex, IncInventors: Mohan Srinivasan, Josephine M. Cardarelli, Haichun Huang
-
Patent number: 7435801Abstract: The present invention provides antibodies and other ligands that specifically bind to KIR2DL4 receptor and stimulate production of interferon gamma. One embodiment is mAb #33 on deposit at ATCC.Type: GrantFiled: April 18, 2003Date of Patent: October 14, 2008Assignee: The United States of America, as represented by the Department of Health and Human ServicesInventors: Eric O. Long, Sumati Rajagopalan
-
Publication number: 20080241154Abstract: Novel TNF receptor polypeptides are disclosed, along with polynucleotides encoding the polypeptides and uses thereof.Type: ApplicationFiled: November 28, 2007Publication date: October 2, 2008Applicant: AMGEN INC.Inventor: Chris Saris
-
Publication number: 20080233046Abstract: The present invention is directed to methods of treating and preventing cancer, such as cancer characterized by differential expression of trefoil factor 3 (TFF3). The methods include administering to a patient an agent that modulates TFF3 activity or expression. The present invention is further directed to reducing the physiological effects of TFF3 expression in cells, including inhibiting cell motility and resistance to apoptosis. Oligonucleotides and antibodies that can modulate expression or activity of TFF3 are also provided.Type: ApplicationFiled: August 5, 2004Publication date: September 25, 2008Inventors: Mary J. Janatpour, Pablo Garcia, Christoph Reinhard
-
Publication number: 20080227959Abstract: The invention provides derivatives of efavirenz and methods of making derivatives of efavirenz. The derivatives include immunogenic compounds for producing antibodies to efavirenz and labeled efavirenz tracers. These compounds are useful in immunoassay methods for determining efavirenz.Type: ApplicationFiled: May 16, 2008Publication date: September 18, 2008Inventors: Mitali Ghoshal, Gerald Sigler, Anlong Ouyang, Richard Root
-
Patent number: 7425447Abstract: The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.Type: GrantFiled: August 11, 2006Date of Patent: September 16, 2008Assignee: Biogen Idec Inc.Inventors: Darrell R. Anderson, Nabil Hanna, Peter Brams
-
Publication number: 20080220431Abstract: The invention provides methods for fusing a first cell with a second cell to form a hybrid cell. The methods involve incubating a first parental cell producing a first partner of a fusogenic binding partner pair on its surface with a second parental cell producing a second partner of the fusogenic binding partner pair on its surface. In certain embodiments, the parental cells are incubated with a known fusogen such as polyethylene glycol and the fusogenic binding partner pair increases the rate of cell fusion. In many embodiments, the first cell is an antibody producing cell, the second cell is an immortal cell, and the hybrid cell is a hybridoma cell that produces a monoclonal antibody. Also provided by the invention are methods for producing hybridoma cells, and methods for screening those cells for production of a monoclonal antibody of interest. The invention further provides systems and kits for carrying out the subject methods.Type: ApplicationFiled: November 8, 2007Publication date: September 11, 2008Inventor: Guo-Liang Yu
-
Patent number: 7422899Abstract: This invention provides antibodies to the prolactin receptor, particularly the human prolactin receptor. Preferred antibodies are capable of blocking prolactin binding to the prolactin receptor, inhibiting signaling through the prolactin receptor, and/or inhibiting proliferation of cancer cells induced by prolactin. Also provided are nucleic acids encoding the antibodies, vectors and host cells comprising the nucleic acids, and uses of the antibodies and nucleic acids.Type: GrantFiled: October 4, 2006Date of Patent: September 9, 2008Assignee: Biogen Idec MA Inc.Inventors: Brian Elenbaas, Matthew B Jarpe, Steven D. Miklasz, Stephen E. Fawell
-
Publication number: 20080213387Abstract: The invention relates to cytotrophoblast stem cells derived from embryonic stem cells; their differentiation into endovascular cytotrophoblast cells; and uses thereof.Type: ApplicationFiled: October 16, 2007Publication date: September 4, 2008Applicant: AXORDIA LIMITEDInventors: Harry MOORE, Paul GERSKOWITCH, Rosliah HARUN
-
Publication number: 20080213170Abstract: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.Type: ApplicationFiled: January 22, 2008Publication date: September 4, 2008Inventors: David S. F. Young, Helen P. Findlay, Susan E. Hahn, Lisa A. Popp
-
Patent number: 7416881Abstract: Yeast cells are engineered to express both a surrogate of a pheromone system protein (e.g., enzymes involved in maturation of ?-factor, transporters of a-factor, pheromone receptors, etc.) and a potential peptide modulator of the surrogate, in such a manner that the inhibition or activation of the surrogate affects a screenable or selectable trait of the yeast cells. Various additional features improve the signal-to-noise ratio of the screening/selection system.Type: GrantFiled: April 5, 1999Date of Patent: August 26, 2008Assignee: Cadus Technologies, Inc.Inventors: Dana M. Fowlkes, Jim Broach, John Manfredi, Christine Klein, Andrew J. Murphy, Jeremy Paul, Joshua Trueheart
-
Publication number: 20080199466Abstract: Immunization of human antibody-producing transgenic mice, which have been created using genetic engineering techniques, with AILIM molecule as an antigen resulted in various human monoclonal antibodies capable of binding to AILIM and capable of controlling a variety of biological reactions (for example, cell proliferation, cytokine production, immune cytolysis, cell death, induction of ADCC, etc.) associated with AILIM-mediated costimulatory signal (secondary signal) transduction. Furthermore, it has been revealed that the human monoclonal antibody is effective to treat and prevent various diseases associated with AILIM-mediated costimulatory signal transduction, being capable of inhibiting the onset and/or advancement of the diseases.Type: ApplicationFiled: May 23, 2007Publication date: August 21, 2008Applicant: JAPAN TOBACCO, INC.Inventors: Takashi Tsuji, Katsunari Tezuka, Nobuaki Hori
-
Publication number: 20080193458Abstract: A novel gene (designated 125P5C8) and its encoded protein are described. While 125P5C8 exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed multiple cancers including prostate, bladder, kidney and colon cancers. Consequently, 125P5C8 provides a diagnostic and/or therapeutic target for cancers, and the 125P5C8 gene or fragment thereof, or its encoded protein or a fragment thereof used to elicit an immune response.Type: ApplicationFiled: September 18, 2007Publication date: August 14, 2008Inventors: Mary Faris, Pia M. Challita-Eid, Steve Chappell Mitchell, Daniel E.H. Afar, Arthur B. Raitano, Aya Jakobovits
-
Publication number: 20080181897Abstract: The invention relates to agonist molecules which specifically bind to or interact with human G-CSF receptor and dimerize the receptor or activate phosphorylation of kinases associated with the receptor to stimulate cell proliferation and differentiation. Such agonist molecules include monoclonal antibodies, or fragments, homologues or analogues thereof, or peptides or organic compounds. Two examples of mouse monoclonal agonist antibodies are disclosed: mAb163-93 and mAb174-74-11.Type: ApplicationFiled: July 7, 2006Publication date: July 31, 2008Inventors: Baofu Ni, Bill N.C. Sun, Cecily R. Y. Sun
-
Publication number: 20080171045Abstract: An isolated antibody that specifically binds to an extracellular domain of human DDR2 and has a therapeutic effect on a solid tumor is described. Also described is a method of treating cancer, the method comprising administering to a patient having a solid tumor an antibody of the present disclosure in a therapeutically effective amount.Type: ApplicationFiled: December 5, 2007Publication date: July 17, 2008Inventors: John LEWICKI, Austin Gurney, Sanjeev Satyal
-
Publication number: 20080166802Abstract: Isolated human monoclonal antibodies which specifically bind to IL-15 (e.g., human IL-15), and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced in a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: ApplicationFiled: July 11, 2007Publication date: July 10, 2008Applicant: Genmab A/SInventors: Jan G.J. van de Winkel, Marcus A. van Dijk, Janine Schuurman, Arnout F. Gerritsen, Ole Baadsgaard, Jorgen Petersen
-
Publication number: 20080160030Abstract: The present invention includes compositions and methods that include antibodies that selectively neutralize a bioactivity of at least two interferon alpha (“IFN?”) protein subtypes for the protein subtypes A, 2, B2, C, F, G, H2, 1, J1, K, 4a, 4b and WA, but does not neutralize at least one bioactivity of IFN? protein subtype D. Examples of bioactivity for measurement include activation of the MxA promoter or antiviral activity and variants, derivatives and fragments thereof. The invention also includes host cells, hybridomas and plasmacytomas that produce antibodies. Because of their unique selectivity and affinity, the antibodies of the present invention are useful to detect IFN? subtypes in sample or tissue and/or for therapeutic applications that include, but are not limited to the treatment and/or amelioration of an IFN? related disorder such as SLE, lupus, type I diabetes, psoriasis, AIDS and Graft versus Host Disease.Type: ApplicationFiled: February 9, 2006Publication date: July 3, 2008Inventors: Jacques F. Banchereau, Kiley Prilliman, Virginia Pascual, Anna Karolina Palucka
-
Publication number: 20080160015Abstract: The present invention is related to a monoclonal anti-idiotypic antibody directed against a Factor VIII inhibitor antibody binding to the C1 domain of Factor VIII, as well as to a cell line producing this monoclonal anti-idiotypic antibody, to the use of this monoclonal anti-idiotypic antibody as medicament, and more particularly to the use thereof for manufacturing a medicament intended for the treatment of haemophilia A.Type: ApplicationFiled: February 26, 2007Publication date: July 3, 2008Inventors: Jean-Guy Gilles, Marc G. Jacquemin, Jean-Marie Saint-Remy, Christian Behrens
-
Publication number: 20080131431Abstract: Provide herein are fusion polypeptides that comprise a CD47 extracellular domain or a variant thereof that is fused to a Fc polypeptide. The fusion polypeptides are useful for treating an immunological disease or disorder in a subject according to the methods described herein. The fusion polypeptides are capable of suppressing immunoresponsiveness of an immune cell, inhibiting production of proinflammatory cytokines, including inhibiting immune complex-induced production of cytokines.Type: ApplicationFiled: May 15, 2007Publication date: June 5, 2008Applicant: Viral Logic Systems Technology Corp.Inventors: Craig A. Smith, Steven Wiley, Ajamete Kaykas, Peter Probst
-
Patent number: 7381800Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.Type: GrantFiled: June 24, 2004Date of Patent: June 3, 2008Assignee: Human Genome Sciences, Inc.Inventors: Yanggu Shi, Paul E. Young, Reinhard Ebner, Daniel R. Soppet, Steven M. Ruben
-
Publication number: 20080124336Abstract: Disclosed are antibodies that inhibit proteolytic release of a soluble KIM-1 polypeptide from KIM-1 expressing cells. Also disclosed are methods of using the antibodies to inhibit shedding of the KIM-1 polypeptide.Type: ApplicationFiled: October 30, 2007Publication date: May 29, 2008Applicants: BIOGEN IDEC MA INC., THE GENERAL HOSPITAL CORPORATIONInventors: Veronique Bailly, Joseph Bonventre
-
Publication number: 20080113385Abstract: In various embodiments, the present invention is drawn to antibodies or antigen-binding fragments thereof that bind to a vertebrate high mobility group box (HMGB) polypeptide, methods of detecting and/or identifying an agent that binds to an HMGB polypeptide, methods of treating a condition in a subject characterized by activation of an inflammatory cytokine cascade and methods of detecting an HMGB polypeptide in a sample.Type: ApplicationFiled: September 20, 2007Publication date: May 15, 2008Inventors: Walter Newman, Shixin Qin, Theresa L. O'Keefe, Robert A. Obar
-
Patent number: 7371568Abstract: The present invention relates to a method for producing a modified foreign chromosome(s) or a fragment(s) thereof, which comprises the steps of: (a) preparing a microcell comprising a foreign chromosome(s) or a fragment(s) thereof, and transferring said foreign chromosome(s) or a fragment(s) into a cell with high homologous recombination efficiency through its fusion with said microcell; (b) in said cell with high homologous recombination efficiency, inserting a targeting vector by homologous recombination into a desired site of said foreign chromosome(s) or a fragment(s) thereof, and/or a desired site of a chromosome(s) derived from said cell with high homologous recombination efficiency, thereby marking said desired site; and (c) in said cell with high homologous recombination efficiency, causing deletion and/or translocation to occur at the marked site of said foreign chromosome(s) or a fragment(s) thereof.Type: GrantFiled: August 23, 1999Date of Patent: May 13, 2008Assignee: Kirin Pharma Kabushiki KaishaInventors: Kazuma Tomizuka, Hitoshi Yoshida, Kazunori Hanaoka, Mitsuo Oshimura, Isao Ishida, Yoshimi Kuroiwa
-
Patent number: 7361345Abstract: Methods for preventing or treating an antibody-mediated disease in a patient are presented, the methods comprising administration of a monoclonal antibody capable of binding to a human CD40 antigen located on the surface of a human B cell, wherein the binding of the antibody to the CD40 antigen prevents the growth or differentiation of the B cell. Monoclonal antibodies useful in these methods, and epitopes immunoreactive with such monoclonal antibodies are also presented.Type: GrantFiled: February 7, 2005Date of Patent: April 22, 2008Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Mark de Boer, Leah B. Conroy
-
Publication number: 20080050812Abstract: The present invention features methods for specifically micropositioning cells on a substratum. Cell-adhesive substances that bind to naturally-occurring or artificially-attached cell-surface moieties are deposited onto the substratum (e.g., using an inkjet printer), after which cells are incubated with the substratum such that they attach to the substratum via the cell-adhesive substances. The methods of the invention can be used to generate complex two- and three-dimensional patterns containing multiple cell types, e.g., for tissue engineering.Type: ApplicationFiled: May 28, 2004Publication date: February 28, 2008Inventors: James W. Cox, Robert J. Klebe
-
Publication number: 20080044807Abstract: A method of treating samples containing hepatitis C virus (HCV) which method comprises treating HCV-containing samples with a treating agent containing (1) an acidifying agent, and (2) a protein-denaturing agent, or an amphoteric surfactant or a cationic surfactant having both a straight chain alkyl group of 10 or more carbon atoms and a tertiary amine or a quaternary ammonium salt in the same molecule, to effect the release of the HCV antigen and the inactivation of antibodies that bind to the HCV antigen, and the like.Type: ApplicationFiled: October 28, 2004Publication date: February 21, 2008Applicant: Advanced Life Science Institute, Inc.Inventors: Katsumi Aoyagi, Kumiko Iida, Naoko Matsubara
-
Patent number: 7326569Abstract: This invention provides hybridoma cell lines producing monoclonal antibodies which inhibit CD14 mediated cell activation. Monoclonal antibodies produced by these cell lines also are provided. The antibodies are useful for the detection of the presence of cell surface and soluble CD14 in a sample. Chimeric and CDR grafted antibodies generated from the above monoclonal antibodies are further provided. Pharmaceutical compositions containing the above biological compositions are provided. These are useful to treat and prevent disorders with CD14 mediated cell activation, such as sepsis.Type: GrantFiled: September 3, 2002Date of Patent: February 5, 2008Assignee: The Scripps Research InstituteInventors: Didier J. Leturcq, Ann M. Moriarty, Richard J. Ulevitch, Peter S. Tobias, John C. Mathison
-
Patent number: 7323331Abstract: A Method for detecting hepatitis B virus as well as a kit and a reagent therefor, comprising using a phosphate buffer that specifically binds to hepatitis B virus, for example a monoclonal antibody that specifically binds to a specific site of core-related protein of hepatitis B virus.Type: GrantFiled: August 10, 2001Date of Patent: January 29, 2008Assignee: Advanced Life Science Institute, Inc.Inventors: Noboru Maki, Tatsuji Kimura, Yoko Oda, Shintaro Yagi
-
Patent number: 7317094Abstract: The process of the invention comprises the implementation of axenic conditions, with use of a liquid single-phase culture medium. For obtaining the amastigote forms, this medium is buffered at a pH of 5.5 to 6.5 and has an osmolarity of at least 400 milliosmoles/kg of liquid, and in particular 400 to 550 milliosmoles/kg of liquid. For obtaining promastigote forms, this medium is buffered at a pH of 7 to 7.5 and has an osmolarity of at least 300 milliosmoles/kg of liquid. This process allows the adaptation and culture in vitro of different stages of tissular parasites, such as leishmanias and T. cruzi or also hematoprotozoa.Type: GrantFiled: October 1, 2002Date of Patent: January 8, 2008Assignee: Institut Francais de Recherche Scientifique pour le Developpement en Cooperation (Orstom)Inventor: Jean-Loup Lemesre
-
Patent number: 7309779Abstract: The present invention provides novel polynucleotides encoding BGS-42 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel BGS-42 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.Type: GrantFiled: June 2, 2006Date of Patent: December 18, 2007Assignee: Bristol-Myers Squibb CompanyInventors: John N. Feder, Shujian Wu, Thomas C. Nelson, Liana M. Lee
-
Patent number: 7273925Abstract: The invention relates to methods and products for regulating lectin complement pathway associated complement activation. The methods include both in vitro and in vivo methods for inhibiting lectin complement pathway associated complement activation. The methods are accomplished by contacting a mammalian cell having surface exposed MBL ligand with an effective amount of a mannan binding lectin inhibitor to inhibit lectin complement pathway associated complement activation. The mannan binding lectin inhibitor may be administered to a subject to prevent cellular injury mediated by lectin complement pathway associated complement activation. The products of the invention include compositions of a mannan binding lectin inhibitor. The mannan binding lectin inhibitor is an isolated mannan binding lectin binding peptide that selectively binds to a human mannan binding lectin epitope and that inhibits lectin complement pathway associated complement activation.Type: GrantFiled: December 15, 1999Date of Patent: September 25, 2007Assignee: Brigham and Women's Hospital, Inc.Inventors: Gregory L. Stahl, Charles D. Collard
-
Patent number: 7259247Abstract: A polypeptide (8F4 molecule) with a T-cell costimulating biological activity is disclosed, as well as monoclonal antibodies against said 8F4 molecule and hybridoma cells which produce the monoclonal antibodies, the use as medicaments of substances which inhibit the biological activity of the disclosed 8F4 polypeptide, in particular monoclonal antibodies, natural or synthetic ligands, agonists or antagonists, in particular for preventing or treating diseases which involve the immune system, the use of said 8F4 molecule or cells containing said 8F4 molecule as medicaments, in particular for preventing or treating diseases which involve the immune system, and the use of substances which specifically recognize the disclosed polypeptide, in particular monoclonal antibodies, natural or synthetic ligands, agonists or antagonists, for diagnosing diseases which involve the immune system.Type: GrantFiled: September 23, 1998Date of Patent: August 21, 2007Assignee: Bundersrespublik Deutschaland Letztvertreten Durch Den Direktor Des Robert-Koch-InstitutesInventor: Richard Kroczek
-
Patent number: 7255859Abstract: The invention concerns monoclonal antibodies against the epitope YPYDVPDYA (SEQ ID NO: 1) which is derived from the haemagglutinin of the human influenza virus and are suitable for the detection and isolation of native haemagglutinin of the human influenza virus, of modified haemagglutinin or of haemagglutinin fusion proteins and have an affinity of >108 M?1, in particular of 109 to 1010 M?1.Type: GrantFiled: October 20, 1997Date of Patent: August 14, 2007Assignee: Roche Diagnostics GmbHInventors: Thomas Emrich, Matthias Hinzpeter, Michael Grol
-
Patent number: 7247474Abstract: This invention provides a method of isolating CD8+ cells which employs an antibody which specifically binds to CD8 molecules present on the surface of CD8+ cells but does not activate the CD8+ cells once bound. This invention also provides related hybridoma cell lines, monoclonal antibodies, antigenic polypeptides, isolated CD8+ cells, and kits.Type: GrantFiled: August 19, 2004Date of Patent: July 24, 2007Assignee: Ortho-McNeil Pharmaceutical, Inc.Inventor: Didier Leturcq
-
Patent number: 7227003Abstract: Anti-TNF antibodies and anti-TNF peptides, specific for tumor necrosis factor (TNF) are useful for in vivo diagnosis and therapy of a number of TNF-mediated pathologies and conditions, as well as polynucleotides coding for anti-TNF murine and chimeric antibodies, peptides, methods of making and using the antibody or peptides in immunoassays and immuno-therapeutic approaches are provided, where the anti-TNF peptide is selected from a soluble portion of TNF receptor, an anti-TNF antibody or structural analog thereof.Type: GrantFiled: June 2, 2005Date of Patent: June 5, 2007Assignees: New York University, Centocor, Inc.Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight, Scott A. Siegel